OYST Key Statistics, Chart & Performance
The current stock price of OYST is 11.17 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -38.83%.
OYST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About OYST
Company Profile
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
Company Info
OYSTER POINT PHARMA INC
202 Carnegie Center, Suite 106
Princeton NEW JERSEY 08540 US
CEO: Jeffrey Nau
Employees: 303
Phone: 16093829032.0
OYSTER POINT PHARMA INC / OYST FAQ
What does OYSTER POINT PHARMA INC do?
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
What is the stock price of OYSTER POINT PHARMA INC today?
The current stock price of OYST is 11.17 USD. The price increased by 0.18% in the last trading session.
Does OYSTER POINT PHARMA INC pay dividends?
OYST does not pay a dividend.
What is the ChartMill rating of OYSTER POINT PHARMA INC stock?
OYST has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is OYSTER POINT PHARMA INC (OYST) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OYST.
OYST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to OYST. When comparing the yearly performance of all stocks, OYST is one of the better performing stocks in the market, outperforming 95.5% of all stocks.
OYST Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OYST. Both the profitability and financial health of OYST have multiple concerns.
OYST Financial Highlights
Over the last trailing twelve months OYST reported a non-GAAP Earnings per Share(EPS) of -6.65. The EPS decreased by -113.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OYST Forecast & Estimates
10 analysts have analysed OYST and the average price target is 28.05 USD. This implies a price increase of 151.12% is expected in the next year compared to the current price of 11.17.
For the next year, analysts expect an EPS growth of -66.47% and a revenue growth 55.43% for OYST